Why did this top broker just downgrade DroneShield shares?

The broker believes its shares are fully valued at current levels.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

DroneShield Ltd (ASX: DRO) shares were out of form again on Monday and sank deep into the red.

The counter drone technology company's shares dropped 21% to end the session at $1.55.

This latest decline means that its shares are now down 43% from last week's 52-week high of $2.72.

A man holds his head in his hands, despairing at the bad result he's reading on his computer.

Image source: Getty Images

Why did DroneShield shares tumble on Monday?

Investors were hitting the sell button yesterday after the company released its second quarter and half year update.

Although DroneShield reported meteoric growth during the first half, its revenue growth slowed markedly in the second quarter.

DroneShield achieved record revenue of $24.1 million for the six months ended 30 June. This represents a 110% on the prior corresponding period. However, the majority of this revenue was generated in the first quarter. For example, first quarter revenue came in at $16.7 million and second quarter revenue came in over 50% lower at $7.4 million.

Given its lofty valuation, it seems that some investors had been pricing in much stronger revenue in the second quarter. And with that not materialising, they were quick to hit the sell button.

Broker reaction

Analysts at Bell Potter have been busy running the rule over the company's update. They note that its first half performance was short of expectations:

DroneShield released its Appendix 4C and Q2 update, which demonstrated continued growth in its core business but was below our 1H expectations. The company delivered record 1H revenue of $24.1m, which was +110% on 1H23 but represented a Q-o-Q fall and was below our expectations of ~$30m.

However, despite this, the broker has increased its long term estimates to reflect its larger sales pipeline. It said:

We have upgraded our revenue forecasts from CY25 onwards based on near-term defence opportunities in the increased sales pipeline and longer-term civilian applications. We now forecast revenue of $129.2m/$162.9m in CY25/CY26 and our EPS forecasts are 4.5c/6.2c. The operating leverage in the business, driven by high gross margins (+70%) and a relatively fixed cost base, will see significant bottom line earnings growth on any upside to our current revenue forecasts.

Shares downgraded

While the above isn't enough for Bell Potter to continue recommending DroneShield shares as a buy, it does believe they have bottomed now.

According to the note, the broker has downgraded its shares to a hold rating (from buy) with an improved price target of $1.60 (from $1.00). This is broadly in line with where DroneShield shares ended yesterday's session.

Bell Potter summarises its downgrade as follows:

Our long-term view of DroneShield remains unchanged, we view the company as a market leader in the still immature counter-drone market and one who will continue to benefit from substantial tailwinds in the defence sector. The company continues to be an attractive vehicle for exposure to popular investment themes, including geopolitical tensions, increasing use of drones and the rise of AI. However, at its current valuation DRO will attract increased scrutiny over its short-term performance and future contract announcements, thus we anticipate continued share price volatility. On this basis, we have downgraded our recommendation to HOLD as we await further evidence of pipeline conversion in the 2H or a more attractive entry point.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: What this leading broker is saying about Lynas shares

Is it bullish or bearish? Let's find out.

Read more »

share buyers, investors, happy investors
Broker Notes

Bell Potter's top ASX 200 holdings revealed

These are the top holdings in the broker's core portfolio.

Read more »

An athlete runs fast with a trail of yellow smoke billowing out behind him.
Broker Notes

Up 139% in a year, why this buy rated ASX All Ords rare earths stock could keep racing higher

A leading broker forecasts more outperformance to come from this surging ASX rare earths stock.

Read more »

Miner with thumbs up at a mine.
Gold

2 ASX gold miners to buy for solid share price gains, according to Barrenjoey

The Africa-focused companies are deeply undervalued after recent sell-offs, the broker says.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A happy family of four on holidays stand on a jetty and cheer.
Broker Notes

Down 40% in 2026, should you buy the big dip in Life360 shares?

A leading analyst offers his outlook for Life360 shares.

Read more »

Buy and sell on yellow paper with pins on them and several share price lines.
Broker Notes

Sell alert! Why this expert is calling time on Nuix and Brainchip shares

A leading analyst forecasts more pain to come for Brainchip and Nuix shares. But why?

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »